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Inactivated polio vaccine introduction in south Asia—1 year on
In 2014, the Global Polio Eradication Initiative advised 
introducing one dose of inactivated polio vaccine (IPV) 
in countries not already using it. The introduction of IPV, 
which contains inactivated forms of poliovirus, aims to 
mitigate the small risk of mainly type 2 live attenuated 
poliovirus in the oral polio vaccine (OPV), causing 
vaccine-associated paralytic poliomyelitis and vaccine-
derived poliovirus. In September, 2014, Nepal was the 
ﬁ rst country supported by GAVI to introduce IPV. Since 
this launch all countries in south Asia (Afghanistan, 
Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, 
and Sri Lanka) have introduced IPV.
After the Nepal launch in 2014, we suggested 
four challenges that lay ahead:1 communication 
diﬃ  culties with IPV introduced with continued use 
of OPV; hesitancy or rejection by caregivers due to 
additional immunisation sessions or injections; ensuring 
that the supply chain could cope with another vaccine 
and that the hardest to reach children would beneﬁ t; 
and misperceptions about polio eradication and the 
need for another type of polio vaccine.  
Through careful preparation for IPV introduction 
in south Asia, these challenges were either overcome 
or transpired to be less important than anticipated. 
Communication messaging to caregivers explained how 
combined OPV and IPV oﬀ ers the best protection against 
polio.2 In Pakistan, because of the focus on OPV campaigns 
and polio eradication, communication emphasised the 
importance of routine immunisation. In other south Asian 
countries, eﬀ orts were designed to convey the importance 
and safety of IPV, ensure continued acceptance of OPV, 
explain beneﬁ ts of multiple injections in one session, 
and to engage professional associations, civil society, and 
religious and community leaders. Countries developed 
training modules and materials for health workers based 
on global guidance.3 Context-speciﬁ c interventions were 
used. In the Maldives, health workers on remote atolls 
were trained via teleconferences.4
Although early experiences in Nepal indicated that 
caregivers might be hesitant about accepting multiple 
injections during one session, health workers suggested 
that consistent communication of the beneﬁ ts of these 
injections would address concerns of the caregivers. 
This approach corresponded with existing evidence 
about positive provider recommendations and 
parental acceptance of multiple injections.5 Bangladesh 
introduced an additional session for the pneumococcal 
conjugate vaccine launched at the same time as IPV, 
but all south Asian countries added IPV to existing 
vaccination sessions.  
Planning avoided supply chain diﬃ  culties from being 
a major challenge. All countries were required by GAVI 
to assess the strength of their supply chain before the 
introduction, and part of the IPV vaccine introduction 
grant was dedicated to improve the supply chain 
as needed.   
After the Nepal launch we noted media stories that 
suggested some misunderstandings regarding IPV,1 
but these stories did not set a trend. In the lead-up to a 
country’s launch of IPV, media was eﬀ ectively engaged 
and often reporting was scientiﬁ cally accurate.6,7 
Despite the successful handling of some of the risks, 
other issues emerged. High coverage of IPV is not 
secured through a vaccine launch. Given that in most 
countries IPV will be administered at the same time as 
diphtheria-tetanus-pertussis (or pentavalent) vaccine, 
coverage of IPV is likely to be similar to these vaccines, 
which is low in some parts of south Asia.  
Similar to previous new vaccine introductions that 
did not raise coverage of existing vaccines,8 IPV has not 
yet been used as an opportunity to increase routine 
coverage and address gaps in equity, perhaps due to 
the necessary speed of introduction. WHO undertook 
a post-introduction evaluation in Bangladesh in 
December, 2015. When completed, this analysis will be 
the ﬁ rst insight into IPV use in south Asia and will assist 
with improvement eﬀ orts. 
Introduction of IPV was slower than anticipated in 
some countries. Initially WHO’s recom mendation was 
to discard open vials after 6 h or at the end of a session, 
irrespective of remaining doses in the vial. However, 
the policy was later revised so that IPV-containing 
vials can be used for up to 28 days after being opened.9 
In Afghanistan this policy change postponed their 
introduction because it was decided to wait until delivery 
of a redesigned vial label. Constrained global supply of 
IPV due to diﬃ  culties in scaling up bulk production and 
quality control delayed introduction in India. Yet, despite 
some delays, all the south Asian countries successfully 
introduced IPV in 2015, as planned.
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With IPV introduced, the next step in polio eradication 
is to switch the type of OPV used in immunisation 
schedules from trivalent OPV (tOPV) to bivalent OPV 
(bOPV). This change will remove live attenuated 
type 2 poliovirus (included in trivalent but not bivalent 
forms of OPV) and its small associated health risks. 
The switch is planned to happen on one day between 
April 17, and May 1, 2016, with remaining tOPV 
destroyed within 2 weeks.10 
South Asian countries have developed plans for 
the switch encompassing procurement, logistics, 
communication, and waste management and disposal. 
Anticipated challenges include ensuring destruction of 
surplus tOPV and communicating to health workers the 
dangers associated with its continued use. Vaccine costs 
for unused tOPV, and regulatory approval for bOPV in 
routine schedules could also be hurdles that aﬀ ect the 
switch.  
Introduction of IPV has been successful in south Asia, 
and many challenges have been overcome. The focus 
is now to ensure high and equitable coverage of IPV to 
maximise the beneﬁ t of removal of tOPV from routine 
vaccination schedules in 2016.   
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